Updated hourlyHourly refreshSun, Oct 25, 2026
Press Release Database
Recent press releases, indexed by topic.
Finance · Biotech & pharma
New York, New York--(August 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline.SO WHAT: If you purchased Capricor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
Aug 19 · 02:47·Newsfile
Biotech & pharma
Capricor Therapeutics (CAPR) Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit
Aug 19 · 02:32·GlobeNewswire
Finance · Biotech & pharma
New York, New York--(August 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead plaintiff deadline.SO WHAT: If you purchased ARS Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
Aug 19 · 02:23·Newsfile
Healthcare · Biotech & pharma
SHANGHAI and HONG KONG, Aug. 18, 2026 -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...
Aug 19 · 01:00·PR Newswire
Finance · Automotive
SHANGHAI, Aug. 18, 2026 -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2026 Interim Results. Business Highlights Cash and cash equivalents were around RMB1,400 million as of...
Aug 19 · 00:15·PR Newswire
Finance · Healthcare
Combined operations deliver unified U.S. and European trial delivery, faster recruitment, and expanded evidence-generation capabilities across pharma, biotech, medtech, diagnostics, and digital health. BOSTON, Aug. 18, 2026 -- Curavit Clinical Research, an innovative clinical...
Aug 18 · 22:19·PR Newswire
SaaS · Industrial
Company says growing federal commitment to ibogaine aligns directly with the pharmaceutical development and manufacturing platform Psyence BioMed has built
Company says growing federal commitment to ibogaine aligns directly with the pharmaceutical development and manufacturing platform Psyence BioMed has built
Aug 18 · 21:23·GlobeNewswire
Biotech & pharma
WICHITA, Kan., Aug. 18, 2026 -- If you've been arrested on drug-related charges, you may be wondering whether entering a drug treatment program could help your case. It's a common question, especially for individuals whose charges are connected to substance use or addiction....
Aug 18 · 20:40·PR Newswire
Biotech & pharma
Chairman and Chief Executive Officer, Roger M. Perlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event on Thursday, August 20, 2026
Aug 18 · 20:15·GlobeNewswire
Healthcare · Biotech & pharma
Follows recent European patent grant and coverage in multiple international markets as Silo continues to strengthen licensed IP portfolio for lead therapeutic program
Aug 18 · 20:15·GlobeNewswire
Finance · Healthcare
WALTHAM, Mass., Aug. 18, 2026 -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that on August 17, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted an aggregate of 11,000 restricted stock units of the Company’s common stock (“RSUs”) to newly hired employees of the Company as an inducement material to such employees’ entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).
Aug 18 · 20:15·GlobeNewswire
Healthcare · Biotech & pharma
ST. LOUIS & DUBLIN, Ohio & MESA, Ariz., August 18, 2026--Gemelli Biotech today announced the publication of a real-world study in Frontiers in Gastroenterology evaluating healthcare resource utilization following IBS-Smart® and Trio-Smart® testing in adults with suspected irritable bowel syndrome (IBS). Gemelli Biotech funded the study and manufactures both tests.
Aug 18 · 17:27·Business Wire